RE: New prolactin patent issuedI agree that this latest patent will eventually be accretive to shareholder value. However, it looks like that SSS is going to need more cash soon... another private placement. Given the state of the credit markets and the lack of enthusiasm for risky investments, the company may have to accept unfavorable terms (low prices and dilutive warrants) for any new equity issue, the anticipation of which is probably what is keeping the SP down. I will wait and see what the terms of any new financing are before adding more shares.